Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

Competing Interest Statement

G.R.S sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ Biotechnology. MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM Vaccines. He receives no personal financial payment for this work. AJP reports grants from UKRI, CEPI and NIHR, during the conduct of the study. AJP is Chair of DHSCs Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in discussions on COVID19 vaccines, and is a member of the WHOs SAGE. The views expressed in this article are those of the authors and do not necessarily represent the views of DHSC, JCVI, NIHR or WHO. The University of Oxford has entered into a partnership with AstraZeneca for the development of a coronavirus vaccine. JSN-V-T is seconded to the Department of Health and Social Care, England (DHSC). The views expressed in this manuscript are those of its authors and not necessarily those of DHSC.

Clinical Trial

ISRCTN27841311 ISRCTN webpage: https://www.isrctn.com/ISRCTN27841311?q=27841311&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search

Clinical Protocols

https://comcovstudy.org.uk/study-protocol

Funding Statement

The work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002) to DIS and GRS, DIS by the UKRI MRC (MR/N00065X/1). DIS and GRS are Jenner Investigators. The Wellcome Centre for Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z). Com-COV2 was funded by the UK Government through the National Institute for Health Research (NIHR), the Vaccine Task Force (VTF) and the Coalition for Epidemic Preparedness Innovations (CEPI). This research was supported by the NIHR Oxford Biomedical Research Centre, NIHR Guy's and St Thomas' Biomedical Research Centre, NIHR King's Clinical Research Facility and NIHR Policy Research Programme (PR-R17-0916-22001), the Southampton NIHR Biomedical Research Centre and Southampton NIHR Clinical Research Facility and delivered through the NIHR-funded National Immunisation Schedule Evaluation Consortium (NISEC). NVX-CoV2373 vaccine was supplied for use in Com-COV2 by Novavax, Inc. MDS and AJP are Jenner Investigators and NIHR Senior Investigators and supported by the Oxford NIHR Biomedical Research Centre.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The South Central - Berkshire Research Ethics Committee gave ethical approval for this work. Reference 21/SC/0119.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes